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Abstract
Background: Tuberculosis kills more people than any other infectious disease, and new regimens are essential. The
primary endpoint for confirmatory phase III trials for new regimens is a composite outcome that includes bacteriological
treatment failure and relapse. Culture methodology is critical to the primary trial outcome. Patients in clinical trials can
have positive cultures after treatment ends that may not necessarily indicate relapse, which was ascribed previously to
laboratory cross-contamination or breakdown of old lesions. Löwenstein-Jensen (LJ) medium was the previous standard
in clinical trials, but almost all current and future trials will use the Mycobacteria Growth Indicator Tube (MGIT) system due
to its simplicity and consistency of use, which will affect phase III trial results.
LJ was used for the definition of the primary endpoint in the REMoxTB trial, but every culture was also inoculated in parallel
into the MGIT system. The data from this trial, therefore, provide a unique opportunity to investigate and compare the
incidence of false ‘isolated positives’ in liquid and solid media and their potential impact on the primary efficacy results.
Methods: All post-treatment positive cultures were reviewed in the REMoxTB clinical trial. Logistic regression models were
used to model the incidence of isolated positive cultures on MGIT and LJ.
Results: A total of 12,209 sputum samples were available from 1652 patients; cultures were more often positive on MGIT than
LJ. In 1322 patients with a favourable trial outcome, 126 (9.5%) had cultures that were positive in MGIT compared to 34 (2.6%)
patients with positive cultures on LJ. Among patients with a favourable outcome, the incidence of isolated positives on MGIT
differed by study laboratory (p< 0.0001) with 21.9% of these coming from one laboratory investigating only 4.9% of patients.
No other baseline factors predicted isolated positives on MGIT after adjusting for laboratory. There was evidence of clustering of
isolated positive cultures in some patients even after adjusting for laboratory, p< 0.0001. The incidence of isolated positives on
MGIT did not differ by treatment arm (p= 0.845, unadjusted). Compared to negative MGIT cultures, positive MGIT cultures were
more likely to be associated with higher grade TB symptoms reported within 7 days either side of sputum collection in
patients with an unfavourable primary outcome (p< 0.0001) but not in patients with a favourable outcome (p=0.481).
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Conclusions: Laboratory cross-contamination was a likely cause of isolated positive MGIT cultures which were clustered
in some laboratories. Certain patients had repeated positive MGIT cultures that did not meet the definition of a relapse.
This pattern was too common to be explained by cross-contamination only, suggesting that host factors were also
responsible. We conclude that MGIT can replace LJ in phase III TB trials, but there are implications for the definition of
the primary outcome and patient management in trials in such settings. Most importantly, the methodologies differ in
the incidence of isolated positives and in their capacity for capturing non-tuberculosis mycobacteria. It emphasises the
importance of effective medical monitoring after treatment ends and consideration of clinical signs and symptoms for
determining treatment failure and relapse.
Keywords: Tuberculosis, MGIT, LJ, Clinical trials, Relapse, Culture media
Background
Tuberculosis kills more people than any other infectious
disease worldwide [1]. Identifying new shorter and safer
treatment regimens is essential for making progress in
controlling the disease. New regimens are being devel-
oped and need to be evaluated in phase III clinical trials.
It is accepted in regulatory guidance and in recent phase
III trials [2–5] that the primary efficacy endpoint is a
composite outcome that includes mainly bacteriological
treatment failure and relapse. Choice of bacteriological
culture method is, therefore, critical for the primary end-
point of phase III trials. Previously this endpoint was
defined by culture usually on Löwenstein-Jensen (LJ)
medium [6]; the quality and sensitivity of this medium
varies significantly depending on its source [7].
It is recognised that patients intensively studied in clinical
trials can have positive cultures in the follow-up period that
may not necessarily indicate clinical relapse [8, 9]. Typically,
subsequent cultures are negative, there is no evidence of
symptomatic recurrence and these patients do not need to
be retreated. Such post-treatment positives have been
attributed to laboratory cross-contamination leading to a
false positive or to the breakdown of an old cavity, releasing
organisms into the sputum from a patient who has no signs
and symptoms of TB and will eventually be classified as
having a favourable outcome, therefore defined as an iso-
lated positive. Evidence for both of these explanations has
been obtained recently using whole genome sequencing of
recurrence strains in a clinical trial [10]. Based on this
knowledge, bacteriological relapse in a phase III clinical trial
continues to be defined as two positive cultures on solid
media at separate visits without an intervening negative
culture [2–5], in line with definitions from earlier trials [6].
In the REMoxTB phase III randomised controlled trial
[4], LJ was used for the definition of the primary end-
point for continuity with previous trials, but the Myco-
bacteria Growth Indicator Tube (MGIT) system was
used in parallel to assess its utility for future trials in
view of its simplicity of use and consistent formulation
and quality control. We have previously shown in this
trial that differences between regimens and therefore the
primary efficacy results were the same irrespective of the
detection method [4]. However, to investigate more spe-
cifically the comparative incidence of isolated positives
in liquid and solid media, and their potential impact on
the primary efficacy results, we reviewed all post-
treatment positive cultures to understand more fully the
impact of using MGIT, which is increasingly used in
trials as the medium of choice [11, 12].
Methods
The REMoxTB trial (Clinicaltrials.gov NCT00864383) was
a randomised placebo-controlled double-blind trial to test
whether two 4-month regimens substituting moxifloxacin
for either ethambutol or isoniazid were non-inferior to the
standard 6-month four-drug regimen, as described previ-
ously [4, 13]. A total of 1931 patients were randomised
across sites in Africa and Asia and followed for 18 months
from randomisation. The trial showed that the two 4 month
moxifloxacin regimens were safe but did not have non-
inferior efficacy compared to the 6 month control in pa-
tients with uncomplicated, smear-positive tuberculosis [4].
During the trial, sputum samples were taken for smear and
culture (LJ and MGIT in parallel) weekly to 8 weeks during
treatment, monthly thereafter to 6 months and 3-monthly
thereafter to 18 months from randomisation. One sputum
sample was collected and inoculated into both LJ and MGIT.
Sputum induction was not performed. The clinical and
laboratory methodology has been described previously [4],
with laboratory procedures described in full in the REMoxTB
laboratory manual (https://www.ucl.ac.uk/infection-immunity/
research/res_ccm/ccm_accor/ccm_remox, accessed 12 June
2017). The per protocol definition of the primary outcome of
favourable and unfavourable was used in the current investiga-
tion, as this was closest to a purely bacteriological outcome.
Any one of the following was classified as an unfavourable
outcome: culture-confirmed or clinical treatment failure;
culture-confirmed relapse; death from TB or respiratory
distress during post-treatment follow-up; non-violent death
during treatment; retreatment for TB with or with culture
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confirmation. A favourable outcome was defined as a patient
having at least two negative culture results at different visits
without an intervening positive culture at the end of follow-
up, not having otherwise had an unfavourable outcome.
For the current investigation, post-treatment follow-up
cultures were defined as all culture results at or after
33 weeks from randomisation, since the first post-
treatment follow-up visit that included all patients in the
trial was at 39 weeks (month 9), and this visit could
occur as early at 33 weeks, accounting for the visit window.
Positive cultures from patients with an unfavourable out-
come (and therefore indicative of relapse and/or treatment
failure) were considered separately from those from
patients with a favourable outcome. The latter were consid-
ered isolated positive cultures, since the patients had subse-
quent negative cultures and were ultimately classified as
having been cured at the end of follow-up without the need
for additional treatment.
For the primary efficacy endpoint, favourable and
unfavourable outcomes were defined using LJ medium.
For this reason, contaminated, missing or suspect values
for LJ results were monitored and patients were often
brought back for repeat sampling. This occurred particu-
larly at the end of follow-up to ensure that patients who
were doing well had documented negative cultures on LJ
to meet the definition of a favourable outcome on the
primary endpoint. This was not done for MGIT results,
since they were not used for the primary endpoint. In
addition, a decision to restart treatment (which would
meet the definition of an unfavourable outcome) was
most often based on the LJ results and clinical consider-
ations without regard to the MGIT results.
Statistical methods
Logistic regression was used to model incidence of post-
treatment positive cultures including, where appropriate,
a patient-level random intercept. The likelihood ratio
test was used to compare models. The following baseline
covariates were evaluated as predictors of positive
cultures: treatment arm, sex, presence of cavitation, his-
tory of smoking, current smoking status, race, HIV sta-
tus, weight, age, CD4 count, BMI, weight band, baseline
MGIT days to positivity. The likelihood ratio test was
used to compare models and forward and backwards
stepwise selection used to develop the model that best
fit the data. The χ2 test for independence was used to
evaluate the association between the result of MGIT cul-
tures and the paired smear or LJ result at the same visit
or the highest grade of TB symptoms reported within
7 days of sputum collection. TB symptoms included any
of the following seven: cough, haemoptysis, fever, night
sweats, shortness of breath, chest pains, unintentional
weight loss.
Results
Considering paired results from the same sputum
samples in post-treatment follow-up visits, cultures were
more often positive in MGIT culture than on LJ. Of
12,209 sputum samples across all 1652 patients, 638
(5.2%) were positive in both media, while 305 (2.5%)
were positive in MGIT but negative on LJ, and only 29
(0.2%) were positive on LJ and negative in MGIT; 152
(1.2%) were contaminated in both media, while 1196
(9.8%) were contaminated on LJ and positive or negative
in MGIT, and 570 (4.7%) were contaminated in MGIT
and positive or negative on LJ. An additional 624 (5.1%)
of samples were MGIT false positive (MGIT instrument
positive, but no organisms detected; these were classified
in the results the same as contaminated) and positive or
negative on LJ. Non-TB mycobacteria (NTM) were more
often identified in MGIT than on LJ, 318 (2.6%) and 88
(0.7%) respectively in all samples, but only in 35 (0.3%)
in both samples. Excluding those samples where one re-
sult was contaminated or missing, there was agreement
between LJ and MGIT in 8801 (93.5%) of 9404 samples.
Of 1322 patients with a protocol-defined favourable
outcome on LJ, 126 (9.5%) had post-treatment follow-up
samples that were positive in MGIT, compared with 34
(2.6%) who had positive samples on LJ (Table 1).
Twenty-four patients (1.8%) had two or more positive
MGIT cultures in post-treatment follow-up on different
visits (Table 1) compared to 1 (<0.1%) with two or more
positive LJ cultures. The two positive LJ cultures were
separated by a negative LJ culture, and therefore this did
not constitute an unfavourable outcome. Of the 24
patients with multiple positive cultures in MGIT, 9 had
intervening negative MGIT cultures between the positive
MGIT cultures, 11 had two positive MGIT cultures with-
out an intervening negative and 4 had more than two
Table 1 Number of patients with positive cultures at or after week 33 (lower bound of the month 9 visit window) on separate visits
in patients with a favourable outcome (per protocol) by culture medium. Two positive cultures on the same day only count as a
single result
Culture
medium
Number of positive cultures at or after week 33 on culture medium in patients with a favourable outcome
0 1 2 3 4 Total
MGIT 1196 (90%) 102 (8%) 17 (1%) 5 (<0.5%) 2 (<0.5%) 1322
LJ 1288 (97%) 33 (2%) 1 (<0.5%) 0 0 1322
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positive MGIT cultures in a row without intervening
negative cultures — despite all these patients having a
favourable outcome with no need for retreatment.
Among patients who had protocol-defined favourable
outcomes, there was clear evidence that the incidence of
isolated positives on MGIT differed by study laboratory
(p < 0.0001) where in one laboratory, 21.9% of all post-
treatment follow-up MGIT cultures in patients who were
deemed to have favourable outcomes were positive
(Fig. 1). This laboratory (A in Fig. 1) was responsible for
the cultures of only 4.6% of all patients in the trial, yet it
reported 8 (33%) of the 24 patients with a protocol-
defined favourable outcome with two or more positive
MGIT cultures in post-treatment follow-up. This indi-
cates that laboratory cross-contamination was likely to
have been a common cause of isolated positives. Fur-
thermore, while we have previously shown that there
was no evidence for an interaction between treatment
and study centre in the primary outcome analysis [4],
patients served by laboratory A (fewer than 100) had a
2.67 increased odds of an unfavourable outcome (95%
confidence interval, CI (1.42, 5.01), p = 0.002, per proto-
col analysis, adjusted for treatment arm) as compared to
other patients in the trial. This suggests laboratory
cross-contamination may also have contributed to the
higher number of patients being classified as bacterio-
logical relapses. No other factors predicted isolated
positives on MGIT in the model adjusted for study
laboratory (all baseline covariates evaluated). There was
clear evidence of clustering of isolated positive in some
patients even after adjusting for study laboratory (random
effects variance 1.23 (standard error 0.373), p < 0.0001),
meaning that the number of patients with two or more
positive MGIT cultures in post-treatment follow-up was
too high to be explained by cross-contamination only.
The incidence of isolated positives on MGIT did not differ
by treatment arm (p = 0.845, unadjusted).
Since two consecutive positives on LJ led to a defined
unfavourable outcome, it was not possible to determine
whether there was clustering of isolated positives on LJ
among patients who had a favourable outcome. The inci-
dence of isolated positives on LJ also differed by study
laboratory, p = 0.0081, although the variability between
laboratories was lower than for MGIT (Fig. 1). No other
factors predicted isolated positives on LJ in the model
adjusted for study laboratory (all baseline covariates evalu-
ated). In particular, incidence of isolated positives on LJ did
not differ by treatment arm (p = 0.451, unadjusted).
We tested the hypothesis that MGIT post-treatment
positive results in patients with a favourable outcome
are not indicative of relapse. Table 2 shows the analysis
of the association between the result of MGIT cultures
at or after week 33 and the paired LJ or smear result at
the same visit, and TB symptoms reported within 7 days
of sputum collection, by per protocol primary outcome.
Compared to negative MGIT cultures, positive MGIT
cultures were more likely to be positive on LJ or smear
irrespective of per protocol primary outcome (p < 0.0001
in each case). However, the odds ratios of a positive
smear or LJ, given a positive MGIT, were much higher
in patients with an unfavourable outcome, 38.0 95% CI
(24.1, 60.0) and 231.7 95% CI (109.1, 492.1) respectively,
than in those with a favourable outcome, 5.8 95% CI
(3.0, 11.2) and 53.4, 95% CI (25.4, 112.4) respectively
(Fig. 2a). Among patients with a favourable primary out-
come, however, only 7% of MGIT positive cultures at or
after week 33 were smear positive when this result was
available and only 13% were LJ positive. In contrast, in
patients with an unfavourable primary outcome, 75% of
MGIT positives were smear positive and 85% LJ positive.
Table 2 also shows that, compared to negative MGIT
cultures, those with a positive MGIT result were more
likely to be associated with higher grade TB symptoms
reported within 7 days of sputum collection in patients
with an unfavourable primary outcome (p < 0.0001) but,
importantly, this pattern was not found in patients with
a favourable outcome, where isolated positive cultures
were not associated with TB symptoms (p = 0.481).
In order to further explore which of the parameters to
which clinicians had access in the clinic might be associ-
ated with MGIT isolated positives, we conducted analyses
Fig. 1 Percentage of isolated positive cultures by culture media and
study laboratory, defined as the percentage of cultures at or after
week 33 (excluding those with contaminated or missing results) that
were positive among patients classified as favourable on the per
protocol primary outcome. Laboratories are sorted by percentage of
isolated positives on MGIT and labelled A to L. Error bars show 95%
exact binomial confidence intervals
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restricted only to positive culture results at or after week
33. There is strong evidence that a MGIT positive culture
in follow-up is more likely to be a true positive (associated
with an unfavourable outcome) if the paired smear or LJ
result is positive, if higher grade TB symptoms are re-
ported, if the number of days to positivity (DTP) is lower
or if there are two positive MGIT results at the same visit
(p < 0.0001 in each case, Table 3). However, Table 3 also
shows that none of these factors can be used to defini-
tively identify an isolated positive (associated with a
favourable outcome). Only 58% of MGIT positive results
that are also smear negative are isolated positives, and
only 69% of MGIT positive results that are also LJ nega-
tive are isolated positives. Similarly, isolated positives oc-
curred in only 42% of MGIT positives where TB
symptoms were absent or < Grade 1 and only 57% of
MGIT positive results with DTP of greater than 15.
Discussion
The development of urgently needed new regimens for
TB is expensive and time-consuming and must be car-
ried out against the backdrop of declining global funding
for TB research and development [14]. It is therefore
essential that pivotal phase III trials make efficient use of
resources and yield reliable results. Critical to this is the
definition of the primary endpoint making the best use
of bacteriological results to distinguish between patients
who are cured and patients who fail treatment or
relapse. Inconsistent results due to even modest differ-
ences in laboratory methodology and processes can
make trial results hard to interpret [15]. For this reason,
we implemented standardised training and laboratory
methodologies in the REMoxTB trial, and culture from
every sputum sample in the trial was done on both LJ
solid and MGIT liquid media. This has allowed us to
Fig. 2 Odds ratios with 95% confidence intervals for smear positivity, LJ positivity or TB symptoms (Grade 1 or higher), separately for patients
with a favourable outcome (blue) or unfavourable outcome (red) for a MGIT result (with negative as reference); b MGIT days to positivity (DTP) < 5
days, 5 to < 15 days, 15 to < 42 days with negative (42 days or more) as reference; c pattern of MGIT results at visit: All negative at least one
negative result and no positive results at that visit. 1 Positive a single positive result and no negative results at that visit, Mixed a single positive
result and at least one negative result at that visit, 2 Positives two positive results and no negative results at that visit
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provide a bridge between previous trials using solid LJ
media and future trials which are expected to use liquid
MGIT media [11, 12, 16].
As expected, there were slightly more positive cultures
and more isolated positive cultures in MGIT than on LJ,
although there was agreement between LJ and MGIT in
the majority of sputum samples where contamination
did not occur in either medium. This result is not sur-
prising given the known performance characteristics of
the MGIT system, which is associated with a lower limit
of detection as well as a more rapid time to positivity
[17–19]. There were also more isolated positive cultures
in MGIT on multiple occasions among patients with a
favourable outcome. This shows for the first time that
even two or more positive results in MGIT may not be
indicative of relapse.
We showed that laboratory cross-contamination was a
cause of isolated positives on MGIT with clustering within
some study laboratories, but we also found evidence of
clustering of isolated positives on MGIT within individual
patients showing that host factors were also responsible. It
is thought that at least a proportion of isolated positives
are derived from pulmonary lesions [8, 10], but we found
that neither cavitation at baseline nor any other baseline
characteristic was associated with an increased incidence
of isolated positive on MGIT, after adjusting for site
laboratory. More work is needed to identify the patient
characteristics and host factors that are more likely to lead
to isolated positives. We showed that post-treatment
positive rates varied by site laboratory, indicating the
importance of managing laboratory services closely. Although
laboratory differences are confounded by geographical differ-
ences, it was notable that of the two laboratories that resulted
in the most isolated positives on MGIT, one was from Asia
and one was from Africa. Cross-contamination between sam-
ples has long been recognised as a challenge in mycobacterial
laboratories, with the contamination rate varying widely [20].
Cross-contamination is a threat to the integrity of the results
of a clinical trial and a risk to patients, since they may
unnecessarily be given extended treatment that may include
more toxic regimens. As with previous studies [18], we have
also shown that the permissive environment for growing
mycobacteria in MGIT leads to an increase in the number of
non-tuberculosis mycobacteria isolated.
Positive cultures in MGIT were more likely to be smear
positive or LJ positive in patients with both favourable and
unfavourable outcomes, yet isolated positive cultures in
MGIT in patients with a favourable outcome were not asso-
ciated with TB symptoms reported within 7 days of sputum
collection, while positive culture results in patients with an
unfavourable outcome were strongly associated with TB
symptoms. This suggests that many of these post-treatment
positives are likely to be contaminants or sub-clinical find-
ings not associated with a clinical manifestation of disease,
even though more likely to be smear and LJ positive.
We showed that a paired positive smear or LJ result,
higher grade TB symptoms, lower days to positivity or more
MGIT positives at the visit were all strongly associated with
Table 3 Association among patients with isolated post-treatment MGIT positive results between primary outcome and paired
information smear results, LJ culture result, TB symptoms, days to positivity on MGIT and pattern of MGIT culture results.
Data restricted to culture results at or after week 33
Per protocol primary outcome
Paired information
N (%)
Favourable Unfavourable Total χ2 test for
independence
Paired smear result from same visit Negative 148 (58%) 105 (42%) 253
Positive 11 (3%) 309 (97%) 320 p < 0.0001
Paired LJ result from same visit Negative 132 (69%) 60 (31%) 192
Positive 19 (5%) 336 (95%) 355 p < 0.0001
Highest grade of TB symptomb
reported within 7 days of patient visit
Absent or < Grade 1 131 (42%) 181 (58%) 312
Grade 1 (mild) 20 (15%) 116 (85%) 136
Grades 2–4 8 (7%) 106 (93%) 114 p < 0.0001
Days to positivity on MGIT <5 6 (5%) 127 (95%) 133
5 to < 15 47 (19%) 202 (81%) 249
15 to < 42 94 (57%) 72 (43%) 166 p < 0.0001
Pattern of MGIT results at visita Mixed 86 (73%) 32 (27%) 118
1 positive 53 (30%) 122 (70%) 175
≥2 positives 20 (7%) 260 (93%) 280 p < 0.0001
aPatterns are as follows: All negative at least one negative result and no positive results at that visit, 1 positive a single positive result and no negative results at
that visit, Mixed a single positive result and at least one negative result at that visit, ≥ 2 positives at least two positive results and no negative results at that visit
bTB symptom as reported on REMoxTB CRF any one of the following seven: cough, haemoptysis, fever, night sweats, shortness of breath, chest pains,
unintentional weight loss
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relapse and could therefore be used, along with the presence
of TB symptoms, by clinicians to give greater confidence in
acting on a positive MGIT result. However, absence of these
factors did not necessarily imply the MGIT positive result
was an isolated positive result.
These data highlight the importance of clinical course
and symptoms in interpreting positive cultures, particularly
in MGIT, after the completion of treatment — in addition
to paired smear results and MGIT days to positivity. This
observation has implications both for patient management
in general and for the primary endpoint definition for
pivotal phase III trials, where no more than 8% of patients
would be expected to have a true unfavourable outcome [4]
and even a small number of erroneously classified relapses
could result in a false interpretation of the trial.
There were a number of limitations with our study. LJ
was used for the primary outcome of the REMoxTB
trial, and therefore decisions to restart treatment after
recurrence of disease were based primarily on LJ results
and clinical course (although MGIT results were usually
also available to study clinicians). While this meant that
we were able to evaluate the incidence of positive cul-
tures on MGIT that did not lead to unfavourable out-
comes, we were not able to do this for LJ. Furthermore,
patients with missing or contaminated LJ results at the
end of follow-up were encouraged to return for follow-
up visits to provide sputum for culture, and therefore
there are fewer patients with missing results on LJ than
on MGIT at the end of follow-up. In the trial an
unfavourable outcome was not always bacteriologically
confirmed on LJ, and so even the per protocol outcome
might include a small number of cases of unnecessary
retreatment. Finally, comparison of the strains of isolated
positives on MGIT using Mycobacterial Interspersed
Repetitive Units (MIRU) typing or whole genome sequen-
cing would have provided more data to distinguish between
strains that matched a patient’s baseline strain and strains
that did not. However, given the large number of isolated
post treatment positives in addition to bacteriological re-
lapses, the cost of whole genome sequencing would be pro-
hibitive. While this means that we cannot definitively
distinguish isolated positives caused by laboratory cross-
contamination (strains that differed) from those that origi-
nated from pulmonary tissue (strains that matched), we can
nevertheless draw conclusions as to likely causality without
strain typing by examining the patterns of isolated positives
within and between patients.
Conclusions
In summary, laboratory cross-contamination was a likely
cause of isolated positives on MGIT with clustering within
some study laboratories, but we also found evidence of
clustering of isolated positives on MGIT within individual
patients that was too high to be explained by cross-
contamination only, showing that host factors were also
responsible. We conclude that MGIT can replace LJ in
phase III TB trials, but there are implications for the def-
inition of the primary outcome and patient management
in trials in such settings. Most importantly, the method-
ologies differ in the incidence of isolated positives and in
their capacity for capturing non-tuberculosis mycobac-
teria. This emphasises the importance of effective medical
monitoring after the end of treatment and consideration
of clinical signs and symptoms in determining treatment
failure and relapse.
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